Gujarat Themis Biosyn Ltd.
Snapshot View

414.00 +10.45 ▲2.6%

03 August 2021, 04:00:00 P.M.
Volume: 11,367

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.gtbl.in
Financial Indicators
Market Cap 586.31 Cr.
Earnings per share (EPS) 20.77 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 19.43 Trailing Twelve Months Ending 2021-03
Industry PE 32.66 Trailing Twelve Months Ending 2021-03
Book Value / Share 48.14 Trailing Twelve Months Ending 2021-03
Price to Book Value 8.38 Calculated using Price: 403.55
Dividend Yield 0.41 Period Ending 2020-03
No. of Shares Subscribed 1.45 Cr. 14,528,702 Shares
FaceValue 5
Company Profile

Gujarat Themis Biosyn Ltd, established in 1981, is a biotech and synthetic product manufacturing company, having plants at Vapi, Hyderabad, with group turnover of over $ 40 million. It has EDMFs, available and WHO approved plants.

The company has world-wide exports to satisfied customers, having customised facility for all products.

The company’s principal activity is to manufacture and distributes pharmaceuticals bulk drugs called rifampicin produced by fermentation process. The company's products include preparations of active pharmaceutical ingredient rifampicin and lovastatin. The company exports its products to Europe and the United States.

Kopran alongwith Cadila Healthcare Ltd., Lyka Labs Ltd., Themis Chemicals Ltd. and Anant & Co., formed Pharmaceutical Business Group (India) Ltd. in 1990.PBG acquired Gujarat Themis Biosyn Ltd (GTBL) as a sick company from BIFR in collaboration with Yuhan Corporation, South Korea and became India’s first producer of Rifampicin.Yuhan has provided technology for Rifampicin from fermentation and invested in equity also.

Business area of the company

  • Pharmaceuticals & Drugs

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+2.59%
1 Week
-3.55%
1 Month
+27.58%
3 Month
+67.14%
6 Month
+69.99%
1 Year
+121.33%
2 Year
+1093.08%
5 Year
+712.56%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 302.71 72.63 38.06 41.85 77.99
Return on Capital Employed (%) 209.07 113.74 80.38 54.67 42.22 44.88 85.96
Return on Assets (%) 10.56 6.02 26.54 29.88 31.50 24.25 18.45 24.07 45.62

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds -14 -10 -5 -1 4 8 12 19 42
Non Curr. Liab. 5 7 6 6 2 1 0 1 5
Curr. Liab. 27 21 15 10 9 12 8 13 24
Minority Int.
Equity & Liab. 17 18 16 15 15 21 20 33 71
Non Curr. Assets 13 14 13 11 11 13 13 25 35
Curr. Assets 5 4 3 3 3 8 8 8 36
Misc. Exp. not W/O
Total Assets 17 18 16 15 15 21 20 33 71

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 9 28 30 31 33 36 39 41 85
Other Income 0 0 0 0 0 0 0 2 2
Total Income 9 29 30 32 33 36 39 43 87
Total Expenditure -11 -25 -24 -25 -27 -30 -33 -34 -53
PBIDT -2 4 7 6 6 6 6 10 34
Interest -1 -1 -1 0 0 0 0 0 -1
Depreciation -1 -2 -1 -1 -1 -1 -1 -1 -1
Taxation -1 -1 -2 -8
Exceptional Items 6
PAT 2 1 5 5 5 4 4 6 24

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 2 0 4 3 4 3 6 1 1
Cash Fr. Inv. -4 -3 0 0 -1 -3 -1 -6 -3
Cash Fr. Finan. 2 2 -3 -3 -3 0 -4 5 2
Net Change 0 0 1 -1 0 0 1 0 0
Cash & Cash Eqvt 1 0 1 0 0 0 1 1 1

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 74.99 74.99 74.99 74.99 74.99 74.99 74.99 74.99 74.99
Public 25.01 25.01 25.01 25.01 25.01 25.01 25.01 25.01 25.01
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 30 Jul 2021
Inter-Se Transfer Of Shares Between The Promoters/ Promoter Group In Accordance With Regulation 10(5) Of SEBI (SAST) Regulations 2011- Signing Of Share Purchase Agreement.
We write this in continuation to our letter dated July 24 2021 on the captioned subject.

Pursuant to the Regulation 30 and other applicable SEBI Reguations we would like to inform you that the Company has received an information from the Pharmaceutical Business Group (India) Limited one of the promoters that a Share Purchase Agreement has been signed today between Pharmaceutical Business Group(India) Limited and Yuhan Corporation also a Promoter.

Please take the same on your records.
Mon, 26 Jul 2021
Revised disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations 2011
The Exchange has received the revised disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Pharmaceutical Business Group India Ltd
Mon, 26 Jul 2021
Revised Disclosure Of Inter-Se Transfer Of Shares Between The Promoters/ Promoters Group In Accordance With Regulation 10(5) Of SEBI (SAST) Regulations 2011.
We refer to your email dated 26th July 2021 received asking for the revised rectify disclosure under regulation 10(5) of Securities and Exchange Board of India {Substantial Acquisition of Shares and Takeovers) Regulations 2011.

In this connection we have received revised rectified disclosure under regulation 10(5) of Securities and Exchange Board of India {Substantial Acquisition of Shares and Takeovers) Regulations 2011 from Pharmaceutical Business Group (India) Limited (Acquirer).

We are forwarding herewith the same.

Please take the same on record.

Technical Scans View Details

Mon, 02 Aug 2021
Close Crossing Last Month Close from Above Close Crossing Last Month Close from Above
Close Within 52 Week High Zone Close Within 52 Week High Zone
Increasing Relative Strength - Sectoral Index Increasing Relative Strength - Sectoral Index
Fri, 30 Jul 2021
High Delivery Percentage High Delivery Percentage
Close Within 52 Week High Zone Close Within 52 Week High Zone

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,816.50 794.85 +2.6%
Divi's Laboratories Ltd. 130,822.92 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. 78,219.21 4,721.20 +0.4%
Cipla Ltd. 74,356.30 927.25 +0.6%
Cadila Healthcare Ltd. 60,574.85 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. 58,218.41 4,076.05 +0.7%
Piramal Enterprises Ltd. 56,317.82 2,507.65 +0.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 30.95 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2021-03 65.93 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.02 4,721.20 +0.4%
Cipla Ltd. Consolidated 2021-03 30.92 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.39 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 387.19 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 42.27 2,507.65 +0.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.88 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2021-03 14.08 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.37 4,721.20 +0.4%
Cipla Ltd. Consolidated 2021-03 4.06 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.66 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.67 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 1.65 2,507.65 +0.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 0.18 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,507.65 +0.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 10.09 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,507.65 +0.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 12.53 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,507.65 +0.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 17,131.99 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,507.65 +0.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 1,546.98 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,507.65 +0.7%